Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?

× No keyword cloud information.

25 in total

1. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.

Authors: Delphine Detaint; Philippe Aegerter; Florence Tubach; Isabelle Hoffman; Henri Plauchu; Yves Dulac; Laurence Olivier Faivre; Marie-Ange Delrue; Patrick Collignon; Sylvie Odent; Maria Tchitchinadze; Catherine Bouffard; Florence Arnoult; Mathieu Gautier; Catherine Boileau; Guillaume Jondeau
Journal: Arch Cardiovasc Dis Date: 2010-07-01 Impact factor: 2.340

2. Deficient CD4+CD25+ T regulatory cell function in patients with abdominal aortic aneurysms.

Authors: Mingdi Yin; Jian Zhang; Yong Wang; Shaoye Wang; Dittmar Böckler; Zhiquan Duan; Shijie Xin
Journal: Arterioscler Thromb Vasc Biol Date: 2010-05-06 Impact factor: 8.311

3. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Authors: Jennifer P Habashi; Daniel P Judge; Tammy M Holm; Ronald D Cohn; Bart L Loeys; Timothy K Cooper; Loretha Myers; Erin C Klein; Guosheng Liu; Carla Calvi; Megan Podowski; Enid R Neptune; Marc K Halushka; Djahida Bedja; Kathleen Gabrielson; Daniel B Rifkin; Luca Carta; Francesco Ramirez; David L Huso; Harry C Dietz
Journal: Science Date: 2006-04-07 Impact factor: 47.728

Review 4. Lessons on the pathogenesis of aneurysm from heritable conditions.

Authors: Mark E Lindsay; Harry C Dietz
Journal: Nature Date: 2011-05-19 Impact factor: 49.962

5. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse.

Authors: K Asai; G P Yang; Y J Geng; G Takagi; S Bishop; Y Ishikawa; R P Shannon; T E Wagner; D E Vatner; C J Homcy; S F Vatner
Journal: J Clin Invest Date: 1999-09 Impact factor: 14.808

6. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.

Authors: Ronald V Lacro; Harry C Dietz; Lisa M Wruck; Timothy J Bradley; Steven D Colan; Richard B Devereux; Gloria L Klein; Jennifer S Li; L LuAnn Minich; Stephen M Paridon; Gail D Pearson; Beth F Printz; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; J Philip Saul; Mario P Stylianou; Lynn Mahony
Journal: Am Heart J Date: 2007-10 Impact factor: 4.749

7. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.

Authors: Benjamin S Brooke; Jennifer P Habashi; Daniel P Judge; Nishant Patel; Bart Loeys; Harry C Dietz
Journal: N Engl J Med Date: 2008-06-26 Impact factor: 91.245

8. Inhibition of aortic aneurysm development in blotchy mice by beta adrenergic blockade independent of altered lysyl oxidase activity.

Authors: M M Moursi; H G Beebe; L M Messina; T H Welling; J C Stanley
Journal: J Vasc Surg Date: 1995-05 Impact factor: 4.268

Review 4. Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature.

Authors: Dianaly T Au; Allison L Arai; William E Fondrie; Selen C Muratoglu; Dudley K Strickland
Journal: Curr Drug Targets Date: 2018 Impact factor: 3.465

4 in total

AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?

1. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.

2. Deficient CD4+CD25+ T regulatory cell function in patients with abdominal aortic aneurysms.

3. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Review 4. Lessons on the pathogenesis of aneurysm from heritable conditions.

5. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse.

6. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.

7. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.

8. Inhibition of aortic aneurysm development in blotchy mice by beta adrenergic blockade independent of altered lysyl oxidase activity.

9. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.

10. Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice.

Review 1. TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.

Review 2. Therapies for Thoracic Aortic Aneurysms and Acute Aortic Dissections.

Review 3. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Review 4. Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature.